Review




Structured Review

Genechem aavs control vectors
Aavs Control Vectors, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/aavs+control+vectors/pm39891907-228-9-22
Average 90 stars, based on 1 article reviews
aavs control vectors - by Bioz Stars, 2026-11
90/100 stars

Images

Related Articles

other:

Article Title: Macrophage-Derived GSDMD Plays an Essential Role in Atherosclerosis and Cross Talk Between Macrophages via the Mitochondria-STING-IRF3/NF-κB Axis
Article Snippet: Eightweek-old male ApoE−/− mice were microinjected with either the macrophage-specific control shRNA-AAV9 (AAV-F4/80-empty vector) or GSDMD shRNA (short hairpin RNA)-AAV9 (AAVF4/80-shGSDMD [shRNA-GSDMD]; 2E+11 vg; Genechem Co, Ltd, Shanghai, China) through tail vein.

Article Title: VILIP3 attenuates neuronal apoptosis and oxidative stress via Nrf2 activation in the pathogenesis of Alzheimer's disease.
Article Snippet: AAV-GFP-VILIP3 and its blank vector (AAV-GFP-Ctrl) (GeneChem, Shanghai, China) were used to overexpress VILIP3 in an in vivo model of AD or to establish the control group.

Article Title: Podoplanin‐<scp>TGF</scp>‐β1 Autocrine Loop: Pivotal Regulator of Islet Stellate Cell Activation via Cell Deformation, Orchestrating Islet Fibrosis in Diabetes
Article Snippet: The activation of islet stellate cells (ISCs) plays an important role in islet fibrosis, which leads to impaired islet function.. While our previous work showed that the expression of the Pdpn gene was significantly increased in activated ISCs, it remains unknown whether Pdpn is responsible for islet fibrosis.. This study was aimed at elucidating its function on islet fibrosis, along with the exploration of the underlying mechanisms.

Article Title: NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis.
Article Snippet: Adipose tissuetargeted adenovirus shRNA mNAT10 (AAV-shRNA-mNAT10) and AAV shRNA mouse negative control (AAV-shRNA-mNC) plasmid were designed and constructed by Genechem Co.,Ltd., Shanghai, China, the vector element sequence was FABP4p-EGFP-MIR155(MCS)-SV40 PolyA.

Article Title: Voluntary exercise alleviates neural functional deficits in Parkinson's disease mice by inhibiting microglial ferroptosis via SLC7A11/ALOX12 axis.
Article Snippet: Preparation of adeno-associated virus (AAV) vector AAV-DJ (DJ serotype) particles engineered to overexpress mouse Alox12 (Gene ID: NM_007440), Slc7a11 (Gene ID: NM_011990), as well as AAV (MG1.2 serotype) particles engineered to silence mouse Alox12 (Gene ID: NM_007440) under the microglial specific CD68 promoter, along with corresponding control AAV particles (vehicle), were purchased from GeneChem Biotech.

Bioprocessing:

Article Title: TEAD1‐Mediated Trans‐Differentiation of Vascular Smooth Muscle Cells into Fibroblast‐Like Cells Contributes to the Stabilization and Repair of Disrupted Atherosclerotic Plaques
Article Snippet: .. AAV targeting mouse TEAD1 (Ad‐TEAD1) and an empty vector (Ad‐Control) were obtained from GENECHEM Incorporation (Shanghai, China). ..

Article Title: CircRNA-0013747 Promotes Mesangial Cell Proliferation in Immunoglobulin A Nephropathy through Modulation of the Warburg Effect
Article Snippet: .. The AAV vectors, specifically designed to silence mmu_ circ_0010297 (AAVsh‐mmu_circ_0010297) and a negative control vector (AAV‐shNC), were obtained from GeneChem, China. ..

Article Title: NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis
Article Snippet: .. Adipose tissue-targeted adenovirus shRNA mNAT10 (AAV-shRNA-mNAT10) and AAV shRNA mouse negative control (AAV-shRNA-mNC) plasmid were designed and constructed by Genechem Co.,Ltd., Shanghai, China, the vector element sequence was FABP4p-EGFP-MIR155(MCS)-SV40 PolyA. .. In addition, the hNAT10 (G641E) mutation (MUT) and wild type (WT) plasmid were constructed by Genechem Co.,Ltd., Shanghai, China.

Negative Control:

Article Title: CircRNA-0013747 Promotes Mesangial Cell Proliferation in Immunoglobulin A Nephropathy through Modulation of the Warburg Effect
Article Snippet: .. The AAV vectors, specifically designed to silence mmu_ circ_0010297 (AAVsh‐mmu_circ_0010297) and a negative control vector (AAV‐shNC), were obtained from GeneChem, China. ..

Article Title: NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis
Article Snippet: .. Adipose tissue-targeted adenovirus shRNA mNAT10 (AAV-shRNA-mNAT10) and AAV shRNA mouse negative control (AAV-shRNA-mNC) plasmid were designed and constructed by Genechem Co.,Ltd., Shanghai, China, the vector element sequence was FABP4p-EGFP-MIR155(MCS)-SV40 PolyA. .. In addition, the hNAT10 (G641E) mutation (MUT) and wild type (WT) plasmid were constructed by Genechem Co.,Ltd., Shanghai, China.

Plasmid Preparation:

Article Title: CircRNA-0013747 Promotes Mesangial Cell Proliferation in Immunoglobulin A Nephropathy through Modulation of the Warburg Effect
Article Snippet: .. The AAV vectors, specifically designed to silence mmu_ circ_0010297 (AAVsh‐mmu_circ_0010297) and a negative control vector (AAV‐shNC), were obtained from GeneChem, China. ..

Article Title: NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis
Article Snippet: .. Adipose tissue-targeted adenovirus shRNA mNAT10 (AAV-shRNA-mNAT10) and AAV shRNA mouse negative control (AAV-shRNA-mNC) plasmid were designed and constructed by Genechem Co.,Ltd., Shanghai, China, the vector element sequence was FABP4p-EGFP-MIR155(MCS)-SV40 PolyA. .. In addition, the hNAT10 (G641E) mutation (MUT) and wild type (WT) plasmid were constructed by Genechem Co.,Ltd., Shanghai, China.

shRNA:

Article Title: NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis
Article Snippet: .. Adipose tissue-targeted adenovirus shRNA mNAT10 (AAV-shRNA-mNAT10) and AAV shRNA mouse negative control (AAV-shRNA-mNC) plasmid were designed and constructed by Genechem Co.,Ltd., Shanghai, China, the vector element sequence was FABP4p-EGFP-MIR155(MCS)-SV40 PolyA. .. In addition, the hNAT10 (G641E) mutation (MUT) and wild type (WT) plasmid were constructed by Genechem Co.,Ltd., Shanghai, China.

Construct:

Article Title: NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis
Article Snippet: .. Adipose tissue-targeted adenovirus shRNA mNAT10 (AAV-shRNA-mNAT10) and AAV shRNA mouse negative control (AAV-shRNA-mNC) plasmid were designed and constructed by Genechem Co.,Ltd., Shanghai, China, the vector element sequence was FABP4p-EGFP-MIR155(MCS)-SV40 PolyA. .. In addition, the hNAT10 (G641E) mutation (MUT) and wild type (WT) plasmid were constructed by Genechem Co.,Ltd., Shanghai, China.

Sequencing:

Article Title: NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis
Article Snippet: .. Adipose tissue-targeted adenovirus shRNA mNAT10 (AAV-shRNA-mNAT10) and AAV shRNA mouse negative control (AAV-shRNA-mNC) plasmid were designed and constructed by Genechem Co.,Ltd., Shanghai, China, the vector element sequence was FABP4p-EGFP-MIR155(MCS)-SV40 PolyA. .. In addition, the hNAT10 (G641E) mutation (MUT) and wild type (WT) plasmid were constructed by Genechem Co.,Ltd., Shanghai, China.



Similar Products

96
Vector Laboratories aav 8 rh 3bnc117 igg1 ls vector
a , The three infants in Group 1 were treated intramuscularly (IM) at birth with the indicated dose of an AAV-1 vector expressing rh-eCD4-IgG2-LS. b , The three infants in Group 2 were treated intravenously (IV) at birth with the indicated dose of an AAV-8 vector expressing rh-eCD4-IgG2-LS. Four weeks later, the Group 2 macaques were injected IM with the same dose of the same AAV-1/rh-eCD4-IgG2-LS vector administered to the Group 1 animals. c , The three infants in Group 3 were injected IM at birth with the indicated dose of an AAV-8 vector expressing <t>rh-3BNC117-IgG1-LS.</t> As the nine infants in Groups 1–3 approached 20 weeks of age, a per-protocol transition to paired housing necessitated the removal of one animal from the study. Because serum concentrations of rh-3BNC117-IgG1-LS had fallen below detection limits after week 12 in the Group 3 infant rh3-3, this animal was removed from the study. d , The six AAV vector-naïve infants in Group 4 were matched in age to those in Groups 1–3. Beginning at postnatal weeks 30–34, all the AAV-treated RMs in Groups 1–3 (except for rh3-3) and the Group 4 controls were subjected to weekly oral challenges with escalating doses of SHIV-AD8 EO .
Aav 8 Rh 3bnc117 Igg1 Ls Vector, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/Goat+IgG+(Control+Antibody)/pmc12460164-56-8-9
Average 96 stars, based on 1 article reviews
aav 8 rh 3bnc117 igg1 ls vector - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
TaKaRa control aav vector
a , The three infants in Group 1 were treated intramuscularly (IM) at birth with the indicated dose of an AAV-1 vector expressing rh-eCD4-IgG2-LS. b , The three infants in Group 2 were treated intravenously (IV) at birth with the indicated dose of an AAV-8 vector expressing rh-eCD4-IgG2-LS. Four weeks later, the Group 2 macaques were injected IM with the same dose of the same AAV-1/rh-eCD4-IgG2-LS vector administered to the Group 1 animals. c , The three infants in Group 3 were injected IM at birth with the indicated dose of an AAV-8 vector expressing <t>rh-3BNC117-IgG1-LS.</t> As the nine infants in Groups 1–3 approached 20 weeks of age, a per-protocol transition to paired housing necessitated the removal of one animal from the study. Because serum concentrations of rh-3BNC117-IgG1-LS had fallen below detection limits after week 12 in the Group 3 infant rh3-3, this animal was removed from the study. d , The six AAV vector-naïve infants in Group 4 were matched in age to those in Groups 1–3. Beginning at postnatal weeks 30–34, all the AAV-treated RMs in Groups 1–3 (except for rh3-3) and the Group 4 controls were subjected to weekly oral challenges with escalating doses of SHIV-AD8 EO .
Control Aav Vector, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/pAAV-ZsGreen1+Vector/pm40461648-311-24-33
Average 94 stars, based on 1 article reviews
control aav vector - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Vigene Biosciences paav9­u6­gfp (adeno­associated virus (aav)) vectors carrying negative control
Effects of <t>miR‐146a</t> on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.
Paav9­U6­Gfp (Adeno­Associated Virus (Aav)) Vectors Carrying Negative Control, supplied by Vigene Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/paav9+u6+shrna+scr++pgk+mcherry/pmc11868994-53-7-20
Average 90 stars, based on 1 article reviews
paav9­u6­gfp (adeno­associated virus (aav)) vectors carrying negative control - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genechem aavs control vectors
Effects of <t>miR‐146a</t> on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.
Aavs Control Vectors, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/aavs+control+vectors/pm39891907-228-9-22
Average 90 stars, based on 1 article reviews
aavs control vectors - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genechem adeno-associated virus (aav) vectors encode sting scramble (negative control, nc
Effects of <t>miR‐146a</t> on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.
Adeno Associated Virus (Aav) Vectors Encode Sting Scramble (Negative Control, Nc, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/aav9/pmc11560960-67-8-15
Average 90 stars, based on 1 article reviews
adeno-associated virus (aav) vectors encode sting scramble (negative control, nc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Obio Technology Corp Ltd aav of the negative control and dj-1 overexpression vectors
Effects of <t>miR‐146a</t> on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.
Aav Of The Negative Control And Dj 1 Overexpression Vectors, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/aav+of+the+negative+control+and+dj+1+overexpression+vectors/pmc11422208-37-1-17
Average 90 stars, based on 1 article reviews
aav of the negative control and dj-1 overexpression vectors - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Jackson Laboratory aav vectors containing egfp operably linked to either a control promoter (ef1a) or a pv-selective re
Effects of <t>miR‐146a</t> on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.
Aav Vectors Containing Egfp Operably Linked To Either A Control Promoter (Ef1a) Or A Pv Selective Re, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/aav1+ef1a+dio+flp+wpre/us12083188-1232-3-30
Average 90 stars, based on 1 article reviews
aav vectors containing egfp operably linked to either a control promoter (ef1a) or a pv-selective re - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Cell Biolabs Inc paav-gfp control vector (aav-400, cellbiolabs inc, san diego, ca)
Effects of <t>miR‐146a</t> on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.
Paav Gfp Control Vector (Aav 400, Cellbiolabs Inc, San Diego, Ca), supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/aav+dj+8+ires+gfp/pmc11364770-84-34-38
Average 90 stars, based on 1 article reviews
paav-gfp control vector (aav-400, cellbiolabs inc, san diego, ca) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
Addgene inc gfp control aav vector
Effects of <t>miR‐146a</t> on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.
Gfp Control Aav Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/AAV-shRNA-ctrl+(Plasmid+%2385741)/pm38588587-154-34-38
Average 94 stars, based on 1 article reviews
gfp control aav vector - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Obio Technology Corp Ltd adeno-associated virus (aav) vectors carrying shrna (sh-sig1r) and a aav control (nc-sig1r)
Effects of <t>miR‐146a</t> on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.
Adeno Associated Virus (Aav) Vectors Carrying Shrna (Sh Sig1r) And A Aav Control (Nc Sig1r), supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+aav+vector/adeno+associated+virus++aav+lung+parkin++with+parkin+gene/pm38693554-72-10-16
Average 90 stars, based on 1 article reviews
adeno-associated virus (aav) vectors carrying shrna (sh-sig1r) and a aav control (nc-sig1r) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


a , The three infants in Group 1 were treated intramuscularly (IM) at birth with the indicated dose of an AAV-1 vector expressing rh-eCD4-IgG2-LS. b , The three infants in Group 2 were treated intravenously (IV) at birth with the indicated dose of an AAV-8 vector expressing rh-eCD4-IgG2-LS. Four weeks later, the Group 2 macaques were injected IM with the same dose of the same AAV-1/rh-eCD4-IgG2-LS vector administered to the Group 1 animals. c , The three infants in Group 3 were injected IM at birth with the indicated dose of an AAV-8 vector expressing rh-3BNC117-IgG1-LS. As the nine infants in Groups 1–3 approached 20 weeks of age, a per-protocol transition to paired housing necessitated the removal of one animal from the study. Because serum concentrations of rh-3BNC117-IgG1-LS had fallen below detection limits after week 12 in the Group 3 infant rh3-3, this animal was removed from the study. d , The six AAV vector-naïve infants in Group 4 were matched in age to those in Groups 1–3. Beginning at postnatal weeks 30–34, all the AAV-treated RMs in Groups 1–3 (except for rh3-3) and the Group 4 controls were subjected to weekly oral challenges with escalating doses of SHIV-AD8 EO .

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: a , The three infants in Group 1 were treated intramuscularly (IM) at birth with the indicated dose of an AAV-1 vector expressing rh-eCD4-IgG2-LS. b , The three infants in Group 2 were treated intravenously (IV) at birth with the indicated dose of an AAV-8 vector expressing rh-eCD4-IgG2-LS. Four weeks later, the Group 2 macaques were injected IM with the same dose of the same AAV-1/rh-eCD4-IgG2-LS vector administered to the Group 1 animals. c , The three infants in Group 3 were injected IM at birth with the indicated dose of an AAV-8 vector expressing rh-3BNC117-IgG1-LS. As the nine infants in Groups 1–3 approached 20 weeks of age, a per-protocol transition to paired housing necessitated the removal of one animal from the study. Because serum concentrations of rh-3BNC117-IgG1-LS had fallen below detection limits after week 12 in the Group 3 infant rh3-3, this animal was removed from the study. d , The six AAV vector-naïve infants in Group 4 were matched in age to those in Groups 1–3. Beginning at postnatal weeks 30–34, all the AAV-treated RMs in Groups 1–3 (except for rh3-3) and the Group 4 controls were subjected to weekly oral challenges with escalating doses of SHIV-AD8 EO .

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques: Plasmid Preparation, Expressing, Injection

a – i , Serum concentrations of rh-eCD4-IgG2-LS ( a – f ) or rh-3BNC117-IgG1-LS ( g – i ) and ADA levels ( a – i ) in infant rhesus macaques in group 1 (rh1-1 ( a ), rh1-2 ( b ) and rh1-3 ( c )), group 2 (rh2-1 ( d ), rh2-2 ( e ) and rh2-3 ( f )), and group 3 (rh3-1 ( g ), rh3-2 ( h ) and rh3-3 ( i )). ADA responses for groups 1–3 are depicted as the serum immunoglobulin reactivity (absorbance values at 450 nm ( A 450 nm )) against plate-bound rh-eCD4-IgG2-LS or rh-3BNC117-IgG1-LS. j , Kaplan–Meier analysis of SHIV acquisition in each experimental group (groups 1–3) versus the control group (group 4) after oral challenges with increasing doses of SHIV-AD8 EO expressed as Gag p27 content. P values were calculated using the Mantel–Cox test. k , l , log 10 -transformed plasma viral loads in the group 4 macaques ( n = 6) ( k ) and in the only group 1 ( l ) monkey (rh1-1) that acquired infection. Empty red bars in l indicate the post-infection serum rh-eCD4-IgG2-LS concentrations.

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: a – i , Serum concentrations of rh-eCD4-IgG2-LS ( a – f ) or rh-3BNC117-IgG1-LS ( g – i ) and ADA levels ( a – i ) in infant rhesus macaques in group 1 (rh1-1 ( a ), rh1-2 ( b ) and rh1-3 ( c )), group 2 (rh2-1 ( d ), rh2-2 ( e ) and rh2-3 ( f )), and group 3 (rh3-1 ( g ), rh3-2 ( h ) and rh3-3 ( i )). ADA responses for groups 1–3 are depicted as the serum immunoglobulin reactivity (absorbance values at 450 nm ( A 450 nm )) against plate-bound rh-eCD4-IgG2-LS or rh-3BNC117-IgG1-LS. j , Kaplan–Meier analysis of SHIV acquisition in each experimental group (groups 1–3) versus the control group (group 4) after oral challenges with increasing doses of SHIV-AD8 EO expressed as Gag p27 content. P values were calculated using the Mantel–Cox test. k , l , log 10 -transformed plasma viral loads in the group 4 macaques ( n = 6) ( k ) and in the only group 1 ( l ) monkey (rh1-1) that acquired infection. Empty red bars in l indicate the post-infection serum rh-eCD4-IgG2-LS concentrations.

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques: Control, Transformation Assay, Clinical Proteomics, Infection

Sera from the macaques in Group 1 (a-c) , Group 2 (d-f) , and Group 3 (g,h) were tested for their ability to neutralize the in vitro infectivity of SHIV-AD8 EO in TZM-bl cells. Neutralizing titers [i.e., inhibitory dilutions at which 50% of neutralization (ID 50 ) was observed] were derived from these assays and plotted against the right y-axis of each panel. As a reference, the serum concentrations of rh-eCD4-IgG2-LS ( a-f ) or rh-3BNC117-IgG1-LS ( g,h ) were plotted against the left y-axis. Sera from the Group 3 macaque rh3-3 were not assayed for anti-SHIV-AD8 EO neutralizing antibodies because this animal was euthanized before the start of the oral SHIV challenge phase (gray shaded boxes).

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: Sera from the macaques in Group 1 (a-c) , Group 2 (d-f) , and Group 3 (g,h) were tested for their ability to neutralize the in vitro infectivity of SHIV-AD8 EO in TZM-bl cells. Neutralizing titers [i.e., inhibitory dilutions at which 50% of neutralization (ID 50 ) was observed] were derived from these assays and plotted against the right y-axis of each panel. As a reference, the serum concentrations of rh-eCD4-IgG2-LS ( a-f ) or rh-3BNC117-IgG1-LS ( g,h ) were plotted against the left y-axis. Sera from the Group 3 macaque rh3-3 were not assayed for anti-SHIV-AD8 EO neutralizing antibodies because this animal was euthanized before the start of the oral SHIV challenge phase (gray shaded boxes).

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques: In Vitro, Infection, Neutralization, Derivative Assay

a – j , The AAV-8-rh-3BNC117-IgG1-LS vector was administered to rhesus macaques across four age groups: group 5 ( a , b ; 48 h, except for rh5-6 (see below)); group 6 ( c , d ; approximately 2 years); group 7 ( e , f ; 4 weeks); group 8 ( g , h ; 8 weeks); and group 9 ( i , j ; 12 weeks). LLOQ, lower limit of quantification. a , c , e , g , i , Serum rh-3BNC117-IgG1-LS concentrations. b , d , f , h , j , Anti-rh-3BNC117-IgG1-LS responses, or ADAs, in each group. k , Serum concentrations of rh-3BNC117-IgG1-LS at week 20 in the group 5 newborns ( n = 5) and group 6 juveniles ( n = 6). l , Comparison of cumulative levels of ADAs produced by the group 5 newborns and group 6 juveniles during the 20 weeks of follow-up. AUC, area under the curve. In k , l , the group 5 infant rh5-6 was not included in the comparisons because it received the AAV-8-rh-3BNC117-IgG1-LS vector 4 weeks after birth. m , Monkeys in groups 3 and 5–9 were divided into three age brackets and their serum rh-3BNC117-IgG1-LS concentrations at week 20 were compared. In k – m , bars correspond to medians and P values were two-sided and calculated using the Mann–Whitney U -test. P values in brackets were calculated without the group 6 outlier rh6-6. n , Correlation between the age (in weeks) of each monkey at the time of AAV inoculation and serum rh-3BNC117-IgG1-LS concentration at week 20.

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: a – j , The AAV-8-rh-3BNC117-IgG1-LS vector was administered to rhesus macaques across four age groups: group 5 ( a , b ; 48 h, except for rh5-6 (see below)); group 6 ( c , d ; approximately 2 years); group 7 ( e , f ; 4 weeks); group 8 ( g , h ; 8 weeks); and group 9 ( i , j ; 12 weeks). LLOQ, lower limit of quantification. a , c , e , g , i , Serum rh-3BNC117-IgG1-LS concentrations. b , d , f , h , j , Anti-rh-3BNC117-IgG1-LS responses, or ADAs, in each group. k , Serum concentrations of rh-3BNC117-IgG1-LS at week 20 in the group 5 newborns ( n = 5) and group 6 juveniles ( n = 6). l , Comparison of cumulative levels of ADAs produced by the group 5 newborns and group 6 juveniles during the 20 weeks of follow-up. AUC, area under the curve. In k , l , the group 5 infant rh5-6 was not included in the comparisons because it received the AAV-8-rh-3BNC117-IgG1-LS vector 4 weeks after birth. m , Monkeys in groups 3 and 5–9 were divided into three age brackets and their serum rh-3BNC117-IgG1-LS concentrations at week 20 were compared. In k – m , bars correspond to medians and P values were two-sided and calculated using the Mann–Whitney U -test. P values in brackets were calculated without the group 6 outlier rh6-6. n , Correlation between the age (in weeks) of each monkey at the time of AAV inoculation and serum rh-3BNC117-IgG1-LS concentration at week 20.

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques: Plasmid Preparation, Comparison, Produced, MANN-WHITNEY, Concentration Assay

Total IgG reactivity to the AAV-8 capsid was measured by ELISA using a fixed dilution (1:1,000) of serum collected at baseline (day 0) and every two weeks thereafter until the last follow up at week 20. All samples from the Group 5 ( n = 6; a ) and Group 6 ( n = 6; b ) animals were tested in the same 384-well ELISA plate and the absorbance values measured at 450 nm for each sample were plotted against time. c , Geometric means of absorbance values measured for Group 5 (yellow hexagons) and Group 6 (gray hexagons) were plotted against time. The two-sided P value was calculated using the Mann-Whitney U test and resulted from comparing Groups 5 and 6 in terms of their cumulative levels of anti-AAV-8 IgG reactivity (area under curve analysis of absorbance values) measured over the 20 weeks of follow-up.

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: Total IgG reactivity to the AAV-8 capsid was measured by ELISA using a fixed dilution (1:1,000) of serum collected at baseline (day 0) and every two weeks thereafter until the last follow up at week 20. All samples from the Group 5 ( n = 6; a ) and Group 6 ( n = 6; b ) animals were tested in the same 384-well ELISA plate and the absorbance values measured at 450 nm for each sample were plotted against time. c , Geometric means of absorbance values measured for Group 5 (yellow hexagons) and Group 6 (gray hexagons) were plotted against time. The two-sided P value was calculated using the Mann-Whitney U test and resulted from comparing Groups 5 and 6 in terms of their cumulative levels of anti-AAV-8 IgG reactivity (area under curve analysis of absorbance values) measured over the 20 weeks of follow-up.

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques: Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

Sixteen pregnant female rhesus macaques at similar gestational stages were selected on the basis of having little or no serum reactivity to AAV-8 by ELISA. These animals were then divided into three groups depending on whether they were treated with recombinant forms of rh-3BNC117-IgG1. The Group A dams ( n = 8) received no bNAb infusion and underwent cesarean (c)-section when their pregnancies reached term at gestational week 24. The only exceptions were dams rhA-1 and rhA-3, which delivered their babies vaginally ahead of schedule. The dams in Groups B and C ( n = 4 each) were treated intravenously with 30 mg/kg of recombinant rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1, respectively, at gestational week 22 and then underwent c-section two weeks later. The offspring of the dams in Groups A-C were transferred to the nursery after birth and then assigned to Groups 7–11. The infants in Groups 7–11 were treated intramuscularly (IM) with 2.0 × 10 12 genome copies ml –1 of an AAV-8/rh-3BNC117-IgG1-LS vector at postnatal weeks 4, 8, or 12, as depicted.

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: Sixteen pregnant female rhesus macaques at similar gestational stages were selected on the basis of having little or no serum reactivity to AAV-8 by ELISA. These animals were then divided into three groups depending on whether they were treated with recombinant forms of rh-3BNC117-IgG1. The Group A dams ( n = 8) received no bNAb infusion and underwent cesarean (c)-section when their pregnancies reached term at gestational week 24. The only exceptions were dams rhA-1 and rhA-3, which delivered their babies vaginally ahead of schedule. The dams in Groups B and C ( n = 4 each) were treated intravenously with 30 mg/kg of recombinant rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1, respectively, at gestational week 22 and then underwent c-section two weeks later. The offspring of the dams in Groups A-C were transferred to the nursery after birth and then assigned to Groups 7–11. The infants in Groups 7–11 were treated intramuscularly (IM) with 2.0 × 10 12 genome copies ml –1 of an AAV-8/rh-3BNC117-IgG1-LS vector at postnatal weeks 4, 8, or 12, as depicted.

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques: Enzyme-linked Immunosorbent Assay, Recombinant, Plasmid Preparation

a-h , Serum concentrations of rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1 in the Group B (a-d) and Group C (e-h) dams following passive infusion of 30 mg/kg these molecules at gestational week 22 (vertical dotted lines). Two weeks later, pregnancies reached term and the animals underwent cesarean (c)-section (vertical solid line). The last two weeks of pregnancy are indicated by a gray box. i , Table listing the concentrations of rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1 in maternal, cord blood, or newborn serum at the time of c-section.

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: a-h , Serum concentrations of rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1 in the Group B (a-d) and Group C (e-h) dams following passive infusion of 30 mg/kg these molecules at gestational week 22 (vertical dotted lines). Two weeks later, pregnancies reached term and the animals underwent cesarean (c)-section (vertical solid line). The last two weeks of pregnancy are indicated by a gray box. i , Table listing the concentrations of rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1 in maternal, cord blood, or newborn serum at the time of c-section.

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques:

While the macaques in groups 10 and 11 were in their final weeks of gestation, their mothers were treated intravenously with recombinant rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1, leading to transplacental transfer of these molecules. The macaques that were prenatally exposed to the bNAb were delivered two weeks later and then treated with the AAV-8-rh-3BNC117-IgG1-LS vector at 8 weeks (group 10) or 12 weeks (group 11) of age. a , c , Serum rh-3BNC117-IgG1-LS concentrations in group 10 ( a ) and group 11 ( c ). ADAs were assessed as described in Fig. for group 10 ( b ) and group 11 ( d ). All samples from groups 7–11 were screened for anti-rh-3BNC117-IgG1-LS antibodies in the same 384-well enzyme-linked immunosorbent assay (ELISA) plate. e , f , Cumulative serum rh-3BNC117-IgG1-LS concentrations ( e ) and ADA levels (absorbance values of anti-rh-3BNC117-IgG1-LS reactivity in serum) ( f ) measured over the first 20 weeks post-intervention were compared between infant macaques exposed to recombinant forms of rh-3BNC117-IgG1 in utero (groups 10 and 11) and age-matched bNAb-naive infants (groups 8 and 9). Bars correspond to medians. All P values were two-sided and calculated using the Mann–Whitney U -test.

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: While the macaques in groups 10 and 11 were in their final weeks of gestation, their mothers were treated intravenously with recombinant rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1, leading to transplacental transfer of these molecules. The macaques that were prenatally exposed to the bNAb were delivered two weeks later and then treated with the AAV-8-rh-3BNC117-IgG1-LS vector at 8 weeks (group 10) or 12 weeks (group 11) of age. a , c , Serum rh-3BNC117-IgG1-LS concentrations in group 10 ( a ) and group 11 ( c ). ADAs were assessed as described in Fig. for group 10 ( b ) and group 11 ( d ). All samples from groups 7–11 were screened for anti-rh-3BNC117-IgG1-LS antibodies in the same 384-well enzyme-linked immunosorbent assay (ELISA) plate. e , f , Cumulative serum rh-3BNC117-IgG1-LS concentrations ( e ) and ADA levels (absorbance values of anti-rh-3BNC117-IgG1-LS reactivity in serum) ( f ) measured over the first 20 weeks post-intervention were compared between infant macaques exposed to recombinant forms of rh-3BNC117-IgG1 in utero (groups 10 and 11) and age-matched bNAb-naive infants (groups 8 and 9). Bars correspond to medians. All P values were two-sided and calculated using the Mann–Whitney U -test.

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques: Recombinant, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, In Utero, MANN-WHITNEY

Four out of the seven AAV-treated macaques in groups 1–3 that resisted oral challenges with SHIV-AD8 EO were kept alive for up to four years, and AAV-driven transgene expression in serum was monitored. These macaques were not re-dosed with AAV vectors after the neonatal period. a – d , Serum concentrations of rh-3BNC117-IgG1-LS ( a , b ) or rh-eCD4-IgG2-LS ( c , d ) and NAb titres against SHIV-AD8 EO for rh3-1 ( a ), rh3-2 ( b ), rh1-2 ( c ), and rh2-3 ( d ). Date of birth (DOB) and date of the last rh-3BNC117-IgG1-LS or rh-eCD4-IgG2-LS measurement are shown. ID 50 , half-maximal infectious dose. e – i , The six macaques in group 5 were kept alive beyond the 20-week follow-up period described in Fig. and their serum concentrations of rh-3BNC117-IgG1-LS ( e ) and NAb titres against SHIV-AD8 EO ( f ) were monitored until the animals reached approximately 2.5 years of age. Beginning at weeks 133–140 post-intervention, the group 5 monkeys and six controls (group 12) were subjected to repeated intrarectal (IR) challenges with a fixed marginal dose of SHIV-AD8 EO . g , Kaplan–Meier analysis of SHIV acquisition in groups 5 and 12. The P value was calculated using the Mantel–Cox test. h , i , Plasma viral loads in the group 12 macaques ( n = 6) ( h ) and in the only group 5 monkey (rh5-2) ( i ) that acquired infection.

Journal: Nature

Article Title: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life

doi: 10.1038/s41586-025-09330-2

Figure Lengend Snippet: Four out of the seven AAV-treated macaques in groups 1–3 that resisted oral challenges with SHIV-AD8 EO were kept alive for up to four years, and AAV-driven transgene expression in serum was monitored. These macaques were not re-dosed with AAV vectors after the neonatal period. a – d , Serum concentrations of rh-3BNC117-IgG1-LS ( a , b ) or rh-eCD4-IgG2-LS ( c , d ) and NAb titres against SHIV-AD8 EO for rh3-1 ( a ), rh3-2 ( b ), rh1-2 ( c ), and rh2-3 ( d ). Date of birth (DOB) and date of the last rh-3BNC117-IgG1-LS or rh-eCD4-IgG2-LS measurement are shown. ID 50 , half-maximal infectious dose. e – i , The six macaques in group 5 were kept alive beyond the 20-week follow-up period described in Fig. and their serum concentrations of rh-3BNC117-IgG1-LS ( e ) and NAb titres against SHIV-AD8 EO ( f ) were monitored until the animals reached approximately 2.5 years of age. Beginning at weeks 133–140 post-intervention, the group 5 monkeys and six controls (group 12) were subjected to repeated intrarectal (IR) challenges with a fixed marginal dose of SHIV-AD8 EO . g , Kaplan–Meier analysis of SHIV acquisition in groups 5 and 12. The P value was calculated using the Mantel–Cox test. h , i , Plasma viral loads in the group 12 macaques ( n = 6) ( h ) and in the only group 5 monkey (rh5-2) ( i ) that acquired infection.

Article Snippet: Both groups were inoculated intramuscularly with the same AAV-8-rh-3BNC117-IgG1-LS vector used in group 3, since AAV-expressed rh-3BNC117-IgG1-LS consistently elicits ADAs in most older monkeys , .

Techniques: Expressing, Clinical Proteomics, Infection

Effects of miR‐146a on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.

Journal: Immunity, Inflammation and Disease

Article Title: MiR‐146a Reduces Inflammation in Experimental Pancreatitis via the TRAF6–NF‐κB Signaling Pathway in Mice

doi: 10.1002/iid3.70163

Figure Lengend Snippet: Effects of miR‐146a on enzymatic changes in AP mice. (A) The expression of miR‐146a after treatment with AAV. (B) Design of the mouse experiment (PBS + NS group ( n = 8), PBS + Cn group ( n = 8), miR‐146a + Cn group ( n = 8), miR‐146a‐sponge + Cn (group n = 8); caerulein, 50 μg/kg, 10 intraperitoneal injections). (C) Serum amylase and (D) lipase activities are shown. PBS + NS: PBS and saline treatment. PBS + Cn: PBS and caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.

Article Snippet: The pAAV9‐U6‐GFP (adeno‐associated virus (AAV)) vectors carrying miR‐146a‐5p (MIMAT0000158; GATCCGTGAGAACTGAATTCCATGGGTTTCAAGAGAACCCATGGAATTCAGTTCTCATTTTTTA), miR‐146a‐5p sponge (MIMAT0000158; CGCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAA) or a negative control were generated (Vigene Bioscience, Jinan, China).

Techniques: Expressing, Saline, Over Expression

Pathological changes in the pancreas and lungs in AP ( n = 8 for each group). (A) Pancreas and lung histology (×200). (B) Pancreas pathology scores and (C) lung histology scores in mice are shown. PBS + NS: saline treatment. PBS + Cn: caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05.

Journal: Immunity, Inflammation and Disease

Article Title: MiR‐146a Reduces Inflammation in Experimental Pancreatitis via the TRAF6–NF‐κB Signaling Pathway in Mice

doi: 10.1002/iid3.70163

Figure Lengend Snippet: Pathological changes in the pancreas and lungs in AP ( n = 8 for each group). (A) Pancreas and lung histology (×200). (B) Pancreas pathology scores and (C) lung histology scores in mice are shown. PBS + NS: saline treatment. PBS + Cn: caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05.

Article Snippet: The pAAV9‐U6‐GFP (adeno‐associated virus (AAV)) vectors carrying miR‐146a‐5p (MIMAT0000158; GATCCGTGAGAACTGAATTCCATGGGTTTCAAGAGAACCCATGGAATTCAGTTCTCATTTTTTA), miR‐146a‐5p sponge (MIMAT0000158; CGCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAA) or a negative control were generated (Vigene Bioscience, Jinan, China).

Techniques: Saline, Over Expression

MiR‐146a affects inflammation in AP ( n = 8 for each group). (A) The expression of MPO in pancreatic and lung tissue (×200). (B) The MPO immunohistochemistry score in pancreatic and lung tissue. (C) The expression of inflammatory cytokines (TNF‐α, IL‐1β, and IL‐6) in pancreatic tissue. PBS + NS: saline treatment. PBS + Cn: caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.

Journal: Immunity, Inflammation and Disease

Article Title: MiR‐146a Reduces Inflammation in Experimental Pancreatitis via the TRAF6–NF‐κB Signaling Pathway in Mice

doi: 10.1002/iid3.70163

Figure Lengend Snippet: MiR‐146a affects inflammation in AP ( n = 8 for each group). (A) The expression of MPO in pancreatic and lung tissue (×200). (B) The MPO immunohistochemistry score in pancreatic and lung tissue. (C) The expression of inflammatory cytokines (TNF‐α, IL‐1β, and IL‐6) in pancreatic tissue. PBS + NS: saline treatment. PBS + Cn: caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.

Article Snippet: The pAAV9‐U6‐GFP (adeno‐associated virus (AAV)) vectors carrying miR‐146a‐5p (MIMAT0000158; GATCCGTGAGAACTGAATTCCATGGGTTTCAAGAGAACCCATGGAATTCAGTTCTCATTTTTTA), miR‐146a‐5p sponge (MIMAT0000158; CGCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAA) or a negative control were generated (Vigene Bioscience, Jinan, China).

Techniques: Expressing, Immunohistochemistry, Saline, Over Expression

MiR‐146a regulates inflammation via the NF‐κB signaling pathway in AP. (A) The expression of P‐P65 and IκBα (×200) and (B) score in the pancreas are shown. (C) Immunofluorescence staining analysis of P65 in the pancreas is shown (×200). PBS + NS: saline treatment. PBS + Cn: caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.

Journal: Immunity, Inflammation and Disease

Article Title: MiR‐146a Reduces Inflammation in Experimental Pancreatitis via the TRAF6–NF‐κB Signaling Pathway in Mice

doi: 10.1002/iid3.70163

Figure Lengend Snippet: MiR‐146a regulates inflammation via the NF‐κB signaling pathway in AP. (A) The expression of P‐P65 and IκBα (×200) and (B) score in the pancreas are shown. (C) Immunofluorescence staining analysis of P65 in the pancreas is shown (×200). PBS + NS: saline treatment. PBS + Cn: caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment. Data shown are the means ± SEM. * p < 0.05, ** p < 0.01.

Article Snippet: The pAAV9‐U6‐GFP (adeno‐associated virus (AAV)) vectors carrying miR‐146a‐5p (MIMAT0000158; GATCCGTGAGAACTGAATTCCATGGGTTTCAAGAGAACCCATGGAATTCAGTTCTCATTTTTTA), miR‐146a‐5p sponge (MIMAT0000158; CGCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAA) or a negative control were generated (Vigene Bioscience, Jinan, China).

Techniques: Expressing, Immunofluorescence, Staining, Saline, Over Expression

The mechanism of miRNA‐146a regulation in AP via the TRAF6–NF‐κB signaling pathway. Immunofluorescence staining analysis of TRAF6 and P‐IKKα/β in the pancreas is shown (×200). PBS + NS: saline treatment. PBS + Cn: caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment.

Journal: Immunity, Inflammation and Disease

Article Title: MiR‐146a Reduces Inflammation in Experimental Pancreatitis via the TRAF6–NF‐κB Signaling Pathway in Mice

doi: 10.1002/iid3.70163

Figure Lengend Snippet: The mechanism of miRNA‐146a regulation in AP via the TRAF6–NF‐κB signaling pathway. Immunofluorescence staining analysis of TRAF6 and P‐IKKα/β in the pancreas is shown (×200). PBS + NS: saline treatment. PBS + Cn: caerulein treatment. MiR‐146a + Cn: miR‐146a overexpression and caerulein treatment. MiR‐146a‐sponge + Cn: miR‐146a‐sponge and caerulein treatment.

Article Snippet: The pAAV9‐U6‐GFP (adeno‐associated virus (AAV)) vectors carrying miR‐146a‐5p (MIMAT0000158; GATCCGTGAGAACTGAATTCCATGGGTTTCAAGAGAACCCATGGAATTCAGTTCTCATTTTTTA), miR‐146a‐5p sponge (MIMAT0000158; CGCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAA) or a negative control were generated (Vigene Bioscience, Jinan, China).

Techniques: Immunofluorescence, Staining, Saline, Over Expression

MiR‐146a affects AP in different animal models. (A) Pancreas histology in AP mice mediated by caerulein combined with LPS and (B) l ‐arginine is shown (×200). PBS + NS: saline treatment. PBS + Cn + LPS: caerulein and LPS treatment. MiR‐146a + Cn + LPS: miR‐146a overexpression and caerulein and LPS treatment. MiR‐146a‐sponge + Cn + LPS: miR‐146a‐sponge and caerulein and LPS treatment. PBS + l ‐arginine: l ‐arginine treatment. MiR‐146a + l ‐arginine: miR‐146a overexpression and l ‐arginine treatment. MiR‐146a‐sponge + l ‐arginine: miR‐146a‐sponge and l ‐arginine treatment. Data shown are the means ± SEM. ** p < 0.01, *** p < 0.001.

Journal: Immunity, Inflammation and Disease

Article Title: MiR‐146a Reduces Inflammation in Experimental Pancreatitis via the TRAF6–NF‐κB Signaling Pathway in Mice

doi: 10.1002/iid3.70163

Figure Lengend Snippet: MiR‐146a affects AP in different animal models. (A) Pancreas histology in AP mice mediated by caerulein combined with LPS and (B) l ‐arginine is shown (×200). PBS + NS: saline treatment. PBS + Cn + LPS: caerulein and LPS treatment. MiR‐146a + Cn + LPS: miR‐146a overexpression and caerulein and LPS treatment. MiR‐146a‐sponge + Cn + LPS: miR‐146a‐sponge and caerulein and LPS treatment. PBS + l ‐arginine: l ‐arginine treatment. MiR‐146a + l ‐arginine: miR‐146a overexpression and l ‐arginine treatment. MiR‐146a‐sponge + l ‐arginine: miR‐146a‐sponge and l ‐arginine treatment. Data shown are the means ± SEM. ** p < 0.01, *** p < 0.001.

Article Snippet: The pAAV9‐U6‐GFP (adeno‐associated virus (AAV)) vectors carrying miR‐146a‐5p (MIMAT0000158; GATCCGTGAGAACTGAATTCCATGGGTTTCAAGAGAACCCATGGAATTCAGTTCTCATTTTTTA), miR‐146a‐5p sponge (MIMAT0000158; CGCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAGGGTCCCAACCCATGGAAATAGTTCTCAA) or a negative control were generated (Vigene Bioscience, Jinan, China).

Techniques: Saline, Over Expression